Global Blood Screening Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Blood Screening Market Size

• The global blood screening market size was valued at USD 3.59 billion in 2025 and is expected to reach USD 5.61 billion by 2033, at a CAGR of 5.75% during the forecast period
• The market growth is largely driven by the increasing prevalence of infectious diseases, growing demand for safe blood transfusions, and advancements in diagnostic technologies, including automated and high-throughput screening systems
• Furthermore, rising awareness among healthcare providers and patients regarding blood safety, along with government initiatives for mandatory screening programs, is establishing blood screening as a critical component of healthcare infrastructure. These converging factors are accelerating the adoption of advanced blood screening solutions, thereby significantly boosting the industry's growth

Blood Screening Market Analysis

• Blood screening, encompassing tests for infectious agents, blood typing, and pathogen detection, is increasingly critical for ensuring the safety of blood transfusions and maintaining public health in both hospital and diagnostic laboratory settings due to its high accuracy, rapid results, and integration with automated testing platforms
• The escalating demand for blood screening is primarily fueled by the rising prevalence of infectious diseases, increasing blood transfusion procedures, and growing regulatory requirements for mandatory screening across hospitals and blood banks
• North America dominated the blood screening market with the largest revenue share of 38.7% in 2025, characterized by advanced healthcare infrastructure, high awareness regarding blood safety, and a strong presence of leading diagnostic companies, with the U.S. witnessing substantial adoption of automated and multiplex screening systems driven by technological innovations and stringent regulatory compliance
• Asia-Pacific is expected to be the fastest growing region in the blood screening market during the forecast period due to increasing healthcare investments, expanding hospital networks, and rising awareness of transfusion safety in emerging economies
• Nucleic Acid Testing segment dominated the blood screening market with a market share of 41.5% in 2025, driven by its high sensitivity, reduced window period for pathogen detection, and growing preference among blood banks and hospitals for advanced screening solutions

Report Scope and Blood Screening Market Segmentation    

Blood Screening Market Trends

Automation and AI-Driven Testing Solutions

• A significant and accelerating trend in the global blood screening market is the integration of automation and artificial intelligence (AI) into testing workflows, enhancing throughput, accuracy, and predictive capabilities
  • For instance, the Roche cobas® 6800/8800 systems utilize AI-driven algorithms to optimize sample processing, reduce human error, and enable high-throughput pathogen detection
• AI-enabled blood screening platforms can learn from historical data to flag abnormal patterns, predict potential contamination risks, and provide intelligent alerts to laboratory personnel for faster intervention
• The seamless integration of automated and AI-assisted testing with laboratory information systems (LIS) enables centralized management of test results, inventory, and reporting, improving overall operational efficiency
• This trend towards more intelligent, rapid, and interconnected screening systems is redefining standards for blood safety and operational efficiency. Consequently, companies such as Grifols are developing AI-powered screening platforms with features such as real-time anomaly detection and automated sample triage
• The demand for automated and AI-enhanced blood screening solutions is growing rapidly across hospital, blood bank, and diagnostic laboratory settings, as healthcare providers increasingly prioritize accuracy, speed, and efficiency in transfusion safety
• There is a growing trend towards multiplex testing panels that can detect multiple pathogens simultaneously, reducing turnaround time and cost per test while improving donor safety

Blood Screening Market Dynamics

Driver

Increasing Need Due to Rising Infectious Diseases and Blood Safety Awareness

• The growing prevalence of infectious diseases, coupled with heightened awareness about blood safety and mandatory screening regulations, is a significant driver for the rising demand for blood screening solutions
  • For instance, in March 2025, Abbott launched its latest Alinity s blood screening platform, aiming to enhance the speed and accuracy of infectious disease detection in blood banks and hospitals
• As healthcare providers recognize the critical importance of ensuring safe blood transfusions, advanced screening technologies offering high sensitivity and rapid results provide a compelling solution over conventional testing methods
• Furthermore, the expansion of voluntary blood donation programs and government initiatives for mandatory donor screening are making blood screening an essential component of healthcare infrastructure
• The convenience of automated testing, integration with laboratory information systems, and the ability to process high sample volumes efficiently are key factors propelling the adoption of modern blood screening solutions in both developed and emerging markets
• Growing partnerships between diagnostic companies and government healthcare programs are accelerating the deployment of advanced blood screening technologies, particularly in emerging regions with expanding healthcare infrastructure
• Increasing focus on personalized medicine and patient safety is driving hospitals and labs to adopt highly sensitive and rapid blood screening solutions to minimize transfusion-related risks

Restraint/Challenge

High Costs and Regulatory Compliance Complexity

• The relatively high cost of advanced blood screening systems, including nucleic acid testing (NAT) and multiplex platforms, poses a significant challenge for widespread adoption, particularly in resource-limited regions
  • For instance, smaller hospitals or blood banks may hesitate to invest in high-throughput AI-enabled screening platforms due to budget constraints
• In addition, stringent regulatory compliance requirements across different regions increase operational complexity, requiring laboratories to adhere to multiple certification standards such as FDA, CE-IVD, and local guidelines
• Addressing these cost and regulatory challenges through scalable, modular screening solutions, training programs, and streamlined compliance workflows is crucial for broader adoption
• While automation and AI enhance efficiency, the upfront investment and ongoing maintenance costs can still limit accessibility, especially in low- and middle-income countries
• Overcoming these challenges through cost-effective solutions, simplified regulatory pathways, and government or private funding support will be vital for sustained growth in the blood screening market
• Limited availability of trained personnel to operate advanced automated and AI-driven systems can hinder adoption in smaller or remote laboratories, emphasizing the need for training and skill development programs
• Data privacy and interoperability issues between different laboratory information systems pose additional challenges, requiring standardized protocols for secure and seamless data sharing across platforms

Blood Screening Market Scope

The market is segmented on the basis of products and services, technology, disease type, and end user

• By Products and Services

On the basis of products and services, the blood screening market is segmented into reagents and kits, instruments, and software and services. The reagents and kits segment dominated the market with the largest revenue share in 2025, driven by their essential role in detecting pathogens, antibodies, and antigens accurately and efficiently. Reagents and kits are widely used across blood banks, hospitals, and diagnostic laboratories, offering high reproducibility and compatibility with automated screening systems. The demand is further strengthened by the continuous development of multiplex kits capable of detecting multiple infectious agents simultaneously, reducing testing time and operational costs. In addition, the widespread adoption of standardized kits ensures compliance with regulatory norms, improving trust among end users. Reagents and kits remain a cost-effective solution for large-scale blood screening, contributing to their dominance. The segment also benefits from ongoing R&D to develop rapid, high-sensitivity testing reagents.

The software and services segment is anticipated to witness the fastest growth from 2026 to 2033, fueled by increasing adoption of laboratory information management systems (LIMS), AI-driven predictive analytics, and cloud-based monitoring platforms. These solutions enable laboratories to manage large volumes of screening data, streamline workflow, and ensure traceability and regulatory compliance. Software-driven automation also enhances efficiency by reducing manual errors and turnaround times. Integration with remote monitoring and telehealth platforms further expands the applications of software and services in emerging markets. Growing investments in digital health and data analytics are accelerating adoption, particularly in blood banks and large hospital networks.

• By Technology

On the basis of technology, the blood screening market is segmented into nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, Western blot assay, next-generation sequencing (NGS), and others. The NAT segment dominated the market with the largest revenue share of 41.5% in 2025, driven by its high sensitivity and ability to detect viral pathogens at early stages, significantly reducing the window period for infection detection. NAT is widely implemented in blood banks and hospitals for screening HIV, Hepatitis B, and Hepatitis C, ensuring transfusion safety. The segment also benefits from technological advancements that allow high-throughput automated processing and multiplex detection. Regulatory mandates and increasing awareness of blood-borne diseases further strengthen NAT adoption. NAT’s reliability and accuracy make it the preferred choice for large-scale screening programs. The segment is supported by continuous innovations in reagents and instrumentation for enhanced precision and speed.

The rapid test segment is expected to witness the fastest growth rate from 2026 to 2033, fueled by the need for point-of-care diagnostics and quick screening in resource-limited settings. Rapid tests offer ease of use, minimal infrastructure requirements, and quick results, making them highly suitable for blood donation drives, emergency screening, and field applications. Technological improvements have enhanced the sensitivity and specificity of rapid tests, broadening their applicability across infectious diseases. The growing demand for decentralized healthcare solutions and urgent diagnostics is further accelerating adoption. Rapid tests are increasingly being integrated with mobile applications and reporting systems for real-time data collection and monitoring.

• By Disease Type

On the basis of disease type, the blood screening market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold and flu, infectious diseases, and others. The infectious diseases segment dominated the market with the largest revenue share in 2025, driven by the high prevalence of transfusion-transmissible infections and the critical need to ensure safe blood supply. Hospitals, blood banks, and diagnostic centers prioritize infectious disease screening to prevent outbreaks and safeguard patient health. The segment benefits from regulatory mandates, continuous advancements in testing technologies, and the rising awareness of blood-borne pathogens. Multiplex and high-throughput testing platforms further support the dominance of infectious disease screening. The segment also sees strong adoption due to government-sponsored blood safety programs in developed and emerging economies. Screening for infectious diseases such as HIV, Hepatitis B and C, and Zika remains a key focus globally.

The oncology segment is expected to witness the fastest growth rate from 2026 to 2033, fueled by rising cancer incidence and the growing use of blood-based biomarkers for early detection and monitoring. Non-invasive liquid biopsy approaches for oncology are gaining popularity, allowing for real-time disease progression monitoring. Technological advancements, including NGS and advanced immunoassays, support early and accurate cancer detection. Increasing investments in precision medicine and personalized healthcare are expanding the demand for oncology-focused blood screening. Hospitals and diagnostic centers are adopting oncology panels to improve patient outcomes and reduce treatment delays. The segment also benefits from growing awareness among patients and healthcare providers about early cancer detection through blood tests.

• By End User

On the basis of end user, the blood screening market is segmented into diagnostic centers, blood banks, hospitals, clinics, and ambulatory surgical centers. The blood banks segment dominated the market with the largest revenue share in 2025, driven by their central role in collecting, storing, and distributing safe blood to hospitals and patients. Blood banks rely heavily on advanced screening technologies, including NAT and ELISA, to ensure transfusion safety and regulatory compliance. High demand for safe blood from emergency services, surgeries, and chronic disease management supports their market dominance. In addition, government regulations and accreditation standards mandate rigorous screening in blood banks. Investment in automation and high-throughput screening solutions further enhances efficiency and accuracy in blood banks. Continuous partnerships with diagnostic technology providers ensure the availability of state-of-the-art screening solutions.

The diagnostic centers segment is expected to witness the fastest growth from 2026 to 2033, fueled by the rising trend of outpatient testing, preventive health check-ups, and early disease detection. Diagnostic centers increasingly adopt automated and rapid screening solutions to provide quick results to patients while maintaining high accuracy. Integration with AI-based analytics and cloud reporting platforms further enhances service delivery. Expanding healthcare access in urban and semi-urban regions of emerging economies is boosting demand for diagnostic center-based blood screening. The convenience, shorter turnaround time, and focus on preventive diagnostics make this segment highly attractive for growth. Partnerships with hospitals and corporate health programs also support rapid expansion.

Blood Screening Market Regional Analysis

• North America dominated the blood screening market with the largest revenue share of 38.7% in 2025, characterized by advanced healthcare infrastructure, high awareness regarding blood safety, and a strong presence of leading diagnostic companies
• Healthcare providers in the region prioritize accuracy, efficiency, and rapid turnaround in blood screening, leading to widespread adoption of automated and high-throughput technologies such as NAT and multiplex testing platforms
• This dominance is further supported by substantial investments in diagnostic laboratories, the presence of key market players, and growing adoption of AI-enabled solutions for predictive analytics and operational efficiency, establishing North America as a leading region for blood safety and screening solutions

U.S. Blood Screening Market Insight

The U.S. blood screening market captured the largest revenue share of 42% in 2025 within North America, fueled by the presence of advanced healthcare infrastructure, stringent regulatory standards, and high awareness regarding blood safety. Hospitals and blood banks are increasingly adopting automated and high-throughput screening technologies to ensure safe transfusions and reduce the risk of infectious disease transmission. The growing trend of preventive healthcare, coupled with technological innovations such as AI-assisted NAT and multiplex testing, further propels the blood screening industry. Moreover, strong government initiatives and mandatory donor screening programs are significantly contributing to market expansion.

Europe Blood Screening Market Insight

The Europe blood screening market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by stringent regulations for blood safety and the growing prevalence of transfusion-transmissible infections. Increasing investments in healthcare infrastructure, coupled with rising adoption of automated and AI-enabled diagnostic solutions, are fostering the demand for advanced blood screening technologies. European hospitals, blood banks, and diagnostic centers prioritize accuracy and compliance, leading to widespread adoption of high-throughput and multiplex testing systems. The region is experiencing significant growth across both routine screening and emergency blood testing applications.

U.K. Blood Screening Market Insight

The U.K. blood screening market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by heightened awareness regarding blood-borne infections and regulatory compliance requirements. The growing trend of voluntary blood donation and preventive healthcare is encouraging hospitals and diagnostic centers to adopt advanced screening technologies. In addition, concerns regarding transfusion safety are motivating both public and private healthcare providers to invest in high-sensitivity NAT and ELISA-based platforms. The U.K.’s strong healthcare infrastructure and technological adoption are expected to continue to stimulate market growth.

Germany Blood Screening Market Insight

The Germany blood screening market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of transfusion safety and growing demand for technologically advanced diagnostic solutions. Germany’s robust healthcare infrastructure, coupled with high adoption of automation and AI-enabled platforms, promotes the use of efficient and reliable blood screening systems in hospitals and blood banks. Integration with laboratory information management systems (LIMS) is becoming increasingly prevalent, enhancing operational efficiency and regulatory compliance. The market also benefits from government-led health programs emphasizing safe blood supply and pathogen detection.

Asia-Pacific Blood Screening Market Insight

The Asia-Pacific blood screening market is poised to grow at the fastest CAGR of 25% during the forecast period of 2026 to 2033, driven by increasing healthcare investments, rising awareness of blood safety, and technological advancements in countries such as China, Japan, and India. The region’s growing number of hospitals, blood banks, and diagnostic centers, supported by government initiatives promoting healthcare infrastructure development, is driving adoption. Furthermore, as APAC becomes a hub for manufacturing diagnostic kits and instruments, the affordability and accessibility of advanced blood screening solutions are expanding to a wider population.

Japan Blood Screening Market Insight

The Japan blood screening market is gaining momentum due to the country’s advanced healthcare system, rising geriatric population, and strong emphasis on preventive healthcare. Hospitals and blood banks increasingly rely on automated and multiplex testing systems to ensure safe blood transfusions and early detection of infectious diseases. The integration of AI-based analysis and rapid testing platforms is fueling growth in laboratory efficiency. Moreover, Japan’s focus on innovation and precision diagnostics is likely to spur demand for high-sensitivity and point-of-care blood screening solutions in both clinical and blood donation settings.

India Blood Screening Market Insight

The India blood screening market accounted for the largest market revenue share in Asia-Pacific in 2025, attributed to rapid expansion of healthcare infrastructure, increasing voluntary blood donations, and rising awareness of transfusion safety. India is witnessing growing adoption of automated and rapid blood screening technologies in hospitals, diagnostic centers, and blood banks. Government initiatives toward safe blood programs, combined with affordable diagnostic kits and instruments from domestic manufacturers, are key factors propelling market growth. The push toward digital health and modernization of blood bank facilities is further accelerating the adoption of advanced screening solutions.

Blood Screening Market Share

The Blood Screening industry is primarily led by well-established companies, including:

• Abbott (U.S.)
• Bio Rad Laboratories, Inc. (U.S.)
• BIOMÉRIEUX (France)
• Grifols, S.A. (Spain)
• DiaSorin S.p.A. (Italy)
• BD (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Siemens Healthineers AG (Germany)
• Ortho Clinical Diagnostics, Inc. (U.S.)
• Hologic, Inc. (U.S.)
• Danaher (U.S.)
• Beckman Coulter, Inc. (U.S.)
• QIAGEN. (Netherlands)
• Revvity, Inc. (U.S.)
• Sysmex Corporation (Japan)
• Cerus Corporation (U.S.)
• Haemonetics Corporation (U.S.)
• Immucor, Inc. (U.S.)
• EKF Diagnostics Holdings plc (U.K.)
• BioGnost Ltd. (Croatia)

What are the Recent Developments in Global Blood Screening Market?

• In November 2025, Roche and Freenome signed a licensing pact valued at over USD 200 million to leverage Freenome’s multi‑omic blood‑based cancer screening tech, indicating crossover between traditional blood screening and early disease detection diagnostics
• In October 2025, the U.S. FDA approved Roche’s Elecsys pTau181 blood test for aiding Alzheimer’s diagnosis, representing a major blood‑based diagnostic milestone with implications for expanded screening use beyond transfusion safety (early detection of neurodegenerative conditions)
• In April 2025, Abbott announced its new Alinity n system, a next‑generation molecular nucleic acid testing platform designed for expanded blood and plasma screening to detect multiple pathogen DNAs/RNAs, signaling strategic entry into high‑sensitivity NAT diagnostics
• In April 2024, Grifols’ Procleix ArboPlex Assay obtained CE mark certification, marking the first automated NAT that simultaneously screens blood donors for four major arboviruses (chikungunya, dengue, West Nile, Zika), addressing emerging risks from vector‑borne diseases
• In March 2024, Roche received FDA approval for the first molecular test to screen U.S. blood donors for malaria, expanding blood screening capabilities beyond traditional infectious agents to include parasitic diseases and enhancing transfusion safety

SKU-1630